Etude des effets d'un antagoniste calcique(la barnidipine) sur la sensibilité des chémorécepteurs et l'activité orthosympathique.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-004288-47-BE

Enrollment

Registered

2005-10-26

Start date

2005-10-04

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

2 groups of patients: one group of patients with systemic hypertension and one another group with control subjects free of disease

Interventions

Trade Name: Vasexten Product Name: Vasexten Pharmaceutical Form: Capsule* INN or Proposed INN: barnidipine hydrochloride CAS Number: 152IS243F5 Other descriptive name: mepirodipine hydrochloride Conce

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: systemic hypertension Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: hypersensitivity to one component of vasexten

Design outcomes

Primary

Measure	Time frame
Main Objective: study the effects of ca channel blockers on the chemoreflex and sympathetic activity;Secondary Objective: precise the mechanisms of chemosensitivity;Primary end point(s): decrease of chemosensitivity	—

Countries

Belgium

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026